NFSG
IBO

Newbridge Financial Services Group’s Impact BioMedical IBO Stock Holding History

Newbridge Financial Services Group’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52 Hold
86
– – ﹤0.01% 1160
2025
Q4 		$43 Hold
86
– – ﹤0.01% 1164
2025
Q3 		$57 Hold
86
– – ﹤0.01% 1268
2025
Q2 		$56 Hold
86
– – ﹤0.01% 1293
2025
Q1 		$75 Hold
86
– – ﹤0.01% 1018
2024
Q4 		$125 Buy
+86
New +$178 ﹤0.01% 1100

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Newbridge Financial Services Group's IBO Position: Q1 2026 in Review

Newbridge Financial Services Group held its Impact BioMedical (IBO) position steady in Q1 2026 at 86 shares worth $52. The position accounts for ﹤0.01% of the portfolio, ranked #1160.

Newbridge Financial Services Group first reported a position in IBO in Q4 2024 and has held it in 6 quarters since. The position peaked at $125 in Q4 2024. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Newbridge Financial Services Group held 86 shares of Impact BioMedical worth $52 as of Q1 2026.
  • Newbridge Financial Services Group left its Impact BioMedical share count unchanged in Q1 2026.
  • Impact BioMedical made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #1160 holding.
  • Newbridge Financial Services Group first reported a position in Impact BioMedical in Q4 2024 and has held it in 6 quarters since.
  • Newbridge Financial Services Group's Impact BioMedical position peaked at $125 in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.